← Back to Search

Other

Drug Combination for Fertility Preservation (Ooxyd Trial)

N/A
Recruiting
Research Sponsored by Clinique Ovo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
Renal and/or hepatic impairment
Tumours of the hypothalamus or pituitary gland
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline oxidative stress at the end of ivf controlled ovarian stimulaition
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if using a combination of two drugs for fertility preservation may increase the number of eggs retrieved.

Who is the study for?
This trial is for women aged 18-37 who are looking to preserve their fertility for personal or medical reasons. It's not suitable for pregnant or breastfeeding women, those with certain hormonal disorders, advanced endometriosis, unexplained bleeding issues, kidney/liver problems, or allergies to the medications used.
What is being tested?
The study tests how oxidative stress affects egg quality during fertility preservation. Participants will undergo IVF and take Rekovelle and Menopur to stimulate follicle production. Blood levels of oxidative stress and cf-DNA will be measured; AI tool Magenta assesses oocyte quality non-invasively.
What are the potential side effects?
There are no direct side effects mentioned from measuring oxidative stress or using the AI tool Magenta in this study. However, IVF-related procedures can include bloating, cramping, mood swings and risks associated with egg retrieval.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have kidney or liver problems.
Select...
My tumor is located in the hypothalamus or pituitary gland.
Select...
My thyroid or adrenal glands are not functioning properly and are not controlled.
Select...
I am taking Coenzyme Q10 during my treatment cycle.
Select...
My ovaries are enlarged for reasons other than polycystic ovarian syndrome.
Select...
I have unexplained bleeding related to female reproductive organs.
Select...
My condition is advanced endometriosis (stage III/IV).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~ivf stimulation cycle
This trial's timeline: 3 weeks for screening, Varies for treatment, and ivf stimulation cycle for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evaluate the correlation between the oxidative stress and the quality of oocytes
Secondary study objectives
Assessment of good quality oocytes
Evaluation of oocyte quality by visualization
Oocytes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Social (elective) preservationExperimental Treatment3 Interventions
Group II: Oncology preservationExperimental Treatment3 Interventions

Find a Location

Who is running the clinical trial?

Clinique OvoLead Sponsor
32 Previous Clinical Trials
41,414 Total Patients Enrolled
Ferring PharmaceuticalsIndustry Sponsor
322 Previous Clinical Trials
1,242,096 Total Patients Enrolled

Media Library

Menopur (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05372549 — N/A
Fertility Preservation Research Study Groups: Oncology preservation, Social (elective) preservation
Fertility Preservation Clinical Trial 2023: Menopur Highlights & Side Effects. Trial Name: NCT05372549 — N/A
Menopur (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05372549 — N/A
Fertility Preservation Patient Testimony for trial: Trial Name: NCT05372549 — N/A
~53 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top